Drug intelligence / Profile preview

MRANK-116

Development stage: Preclinical
Lead developer: MindRank
Modality: Small Molecules

Overview

MRANK-116 is a preclinical-stage small molecule drug candidate being developed by MindRank for the treatment of obesity. Discovered using the company's proprietary AI-driven drug discovery platform, the specific biological target of the compound has not yet been disclosed by the sponsor. It represents part of MindRank's expanding pipeline in metabolic diseases, which also includes other AI-designed compounds like MRANK-808.

Beyond the preview

Go deeper on MRANK-116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRANK-116.

Explore the full profile